Tracking the path of chemotherapy drugs in real time and at a cellular level could revolutionize cancer care and help doctors sort out why two patients might respond differently to the same treatment. Researchers at The Ohio State University have found a way to light up a common cancer drug so they can see where the chemo goes and how long it takes to get there.

Patients suffering organ failure caused by a common inflammatory condition could be helped by a new therapy. Scientists have discovered an experimental medicine that protects against organ damage caused by a condition called acute pancreatitis. The research offers hope for the illness, which has no current treatment, and which affects thousands of people in the UK each year and places a huge burden on intensive care facilities.

A new method for labeling molecules with radioactive elements could let chemists more easily track how drugs under development are metabolized in the body. Chemists consider thousands of compounds in the search for a new drug, and a candidate's metabolism is a key factor that must be evaluated carefully and quickly.

From horny goat weed to ginseng and maca, over-the-counter dietary supplements sold to improve male sexual health contain a wide variety of "natural" ingredients. Researchers from Wake Forest Baptist Medical Center reviewed the scientific evidence for the most common ingredients to determine if they are effective - and most importantly - safe.

The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials. The journal is a spin-off of the well-established title Contemporary Clinical Trials.

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center (ACC) in the University of Pennsylvania published this month in JAMA Oncology.

To create treatments for a disease without any, scientists need to study and understand the driving forces behind the faulty biology. Today, researchers at the University of North Carolina School of Medicine announced the first-ever evidence-based description of the neuronal protein clumps thought to be important in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, a fatal neurodegenerative condition.